Although the impact of AMR on human health and food production has received considerable attention, there is still inadequate political commitment and stakeholder engagement in these areas globally and at country level.

The Global Leaders Group on AMR (GLG) was established following the Interagency Coordination Group (IACG) recommendation on AMR to strengthen AMR's global political momentum and leadership. The Global Leaders Group (GLG) includes members from Member States, civil society and the private sector.

The mission of the GLG is to collaborate globally with governments, agencies, civil society, and the private sector through a One Health approach to advise on and advocate for prioritized political actions for the mitigation of drug-resistant infections through responsible and sustainable access and use of antimicrobials.

The GLG is co-chaired by Their Excellencies Sheikh Hasina, Prime Minister of Bangladesh and Mia Amor Mottley, Prime Minister of Barbados.

Strengthen global political momentum

The GLG is about catalyzing political action and bringing together political leaders to address the enormous challenges of AMR and seize the opportunities it presents to create a healthier, safer, more prosperous and equitable world. Through its work, the GLG aims to contribute to:

• AMR being widely recognized as a major threat to health and development in existing and future national and global frameworks and targets and mitigation of its impact through a One Health approach;
• Infection prevention and control, including water, sanitation and hygiene and vaccination programmes and waste management tools being prioritized as interventions to mitigate AMR across the human health, animal health, food, plant and environmental eco-systems;
• Responsible and sustainable use of antimicrobials across the human health, animal health, food, plant and environmental eco-systems;
• Global and national actions on AMR being guided by science- and risk-based data on surveillance and monitoring of antimicrobial use and resistance across all sectors;
• Increased, dedicated public and private sector investment to combat AMR across all One Health sectors with each country having a funded, implemented and sustainable national action plan on AMR;
• Support for new and existing funding mechanisms to provide external financial support for the implementation of national action plans on AMR in low- and middle-income countries;
• Specific commitments by governments and the private sector to advance policies that attract sustainable, long term research and development investments in new antimicrobials (particularly antibiotics), vaccines, diagnostics, waste management tools and safe and effective alternatives to antimicrobials, including mechanisms that recognize the value of novel antimicrobials and systems that enable appropriate patient access; and
•  Better evidence on AMR in the environmental eco-system can be used to understand risks and mitigate the development and transmission of AMR.

The GLG will work with all stakeholders and sectors in the global response to AMR and undertake a range of activities, including:

• Mapping the status of key issues and developing advocacy statements;
• Advocating around and/or engaging in key global and regional fora such as the G7, G20, regional, political, and economic blocs and relevant high-level meetings on health and development;
• Advocating for a High-level Meeting on AMR at the UN General Assembly in 2024 or 2026;
• Advocating for inclusion of AMR in any global pandemic treaty;
• Engaging with the Quadripartite and supporting their mandates;
• Supporting the establishment of the Independent Panel on Evidence for Action on AMR Multi-Stakeholders Partnership Platform;
• Advocating for developing global and national targets for responsible and sustainable antimicrobial access and use across the human health, animal health, food, plant and environmental eco-systems.